The United Laboratories International Holdings ( (HK:3933) ) has issued an update.
The United Laboratories International Holdings Limited announced that its subsidiary, Zhuhai United Bio-Pharmaceutical Co., Ltd, received approval from China’s National Medical Products Administration for its Liraglutide Injection, designed for blood glucose control in type 2 diabetes patients. This approval, part of a broader strategy to enhance manufacturing efficiency and product quality, positions the company as a leader in the biopharmaceutical industry, ensuring a stable market supply and benefiting a wide patient population.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a biopharmaceutical company incorporated in the Cayman Islands. It focuses on developing innovative drugs and biosimilars, particularly targeting the GLP-1 segment, which enhances its market competitiveness in the biopharmaceutical field.
YTD Price Performance: 28.16%
Average Trading Volume: 13,212
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.62B
See more data about 3933 stock on TipRanks’ Stock Analysis page.